Niki Arrowsmith09.24.12
Medical device research organization NAMSA has opened its newest office in Shanghai, China. The company is headquartered in Northwood, Ohio.
The new office is intended to provide NAMSA’s China-based clients with convenient access to its services, as well as increased efficiency. Company officials hope the Shanghai office will allow NAMSA to better support Chinese manufacturers in meeting European and U.S. regulatory requirements. Additionally, the company also is better positioned to assist device manufacturers outside China to meet the necessary standards for marketing products in China.
“This expansion benefits all of NAMSA’s current and potential clients,” said An Liu, general manager of NAMSA China. “Chinese manufacturers can trust in our proven ability to successfully support meeting European and U.S. regulatory requirements, while those manufacturers outside China aiming to distribute products within China can rely on our expertise and proximity for convenient assistance in meeting the country's regulatory demands.”
In his new role, Liu is responsible for establishing and developing NAMSA China business. He previously served as director of biostatistics and data management for NAMSA. Before joining the organization, Liu served as statistics manager for Medtronic Inc.
“NAMSA is pleased to be in a position to expand and better serve our partners with world-class expertise in regulatory, non-clinical and clinical research services,” said Terence Langenderfer, director of global marketing, NAMSA. “It has always been our intention to provide the best strategic guidance and tactical support in the most cost-effective and seamless manner. This expansion in China supports that mission.”
NAMSA is a global contract research organization that provides regulatory, clinical, and compliance services to medical device and healthcare product manufacturers.
The new office is intended to provide NAMSA’s China-based clients with convenient access to its services, as well as increased efficiency. Company officials hope the Shanghai office will allow NAMSA to better support Chinese manufacturers in meeting European and U.S. regulatory requirements. Additionally, the company also is better positioned to assist device manufacturers outside China to meet the necessary standards for marketing products in China.
“This expansion benefits all of NAMSA’s current and potential clients,” said An Liu, general manager of NAMSA China. “Chinese manufacturers can trust in our proven ability to successfully support meeting European and U.S. regulatory requirements, while those manufacturers outside China aiming to distribute products within China can rely on our expertise and proximity for convenient assistance in meeting the country's regulatory demands.”
In his new role, Liu is responsible for establishing and developing NAMSA China business. He previously served as director of biostatistics and data management for NAMSA. Before joining the organization, Liu served as statistics manager for Medtronic Inc.
“NAMSA is pleased to be in a position to expand and better serve our partners with world-class expertise in regulatory, non-clinical and clinical research services,” said Terence Langenderfer, director of global marketing, NAMSA. “It has always been our intention to provide the best strategic guidance and tactical support in the most cost-effective and seamless manner. This expansion in China supports that mission.”
NAMSA is a global contract research organization that provides regulatory, clinical, and compliance services to medical device and healthcare product manufacturers.